Table 3.

Tumor Responses (N=27)

Responses	Anlotinib and Liposomal Doxorubicin
	No	%
CR	2	7.4
PR	9	33.3
SD	11	40.7
PD	5	18.5
ORR	11	40.7
DCR	22	81.5
Median PFS	7.2 months
PFR 3 months		81.5
PFR 6 months		59.3

Abbreviations: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate; PFS, progression-free survival; PFR, progression-free rate.